Amgen Inc. $AMGN Shares Purchased by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 56.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 4,978 shares of the medical research company’s stock after acquiring an additional 1,788 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Amgen were worth $1,626,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC increased its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC boosted its holdings in Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after buying an additional 416 shares during the last quarter. Finally, Ieq Capital LLC increased its stake in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after buying an additional 2,611 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on AMGN shares. Canaccord Genuity Group started coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Truist Financial increased their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Mizuho raised their price objective on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Finally, Guggenheim lowered their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $357.12.

Amgen Stock Performance

Shares of Amgen stock opened at $329.59 on Tuesday. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a market cap of $177.87 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 3.33 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The business’s 50 day moving average price is $353.07 and its 200 day moving average price is $342.21.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business earned $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen Inc. will post 22.36 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen’s dividend payout ratio is currently 70.15%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.